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Abstract
Human immunodeficiency virus (HIV) is an infection 
that came into existence decades back; it spread across 
the African countries in the late 1970s, and is currently 
endemic across the world. HIV is a major public health 
problem all over the world, as it has claimed more than 
35million lives. There were around 36.9 million individ-
uals living with HIV at the end of 2017, and Sub-Saharan 
Africa remains the most affected by HIV infection with 
1 in 25 adults (4.1%) living with the virus, accounting 
for 70% of the people living with HIV worldwide. Unfor-
tunately, Sub-Saharan Africa continues to be the con-
tinent with the highest cases of infections and deaths 
from HIV/AIDS even after the implementation of various 
HIV/AIDS prevention methods. Fortunately, pre-expo-
sure prophylaxis (PrEP) offers the world a novel way 
of curtailing the HIV/AIDS epidemic, as PrEP is highly 
effective for preventing HIV if it is used as prescribed. 
This paper discusses the urgent need for the use of 
PrEP in the prevention of HIV/AIDS in Sub-Saharan Af-
rica. It is a review paper in which the meaning of PrEP 
was discussed, people who need PrEP were identified, 
the rationale for the use of PrEP for the prevention of 
HIV/AIDS in Sub-Saharan Africa were highlighted, and 
probable obstacles to the successful implementation of 
PrEP for the prevention of HIV/AIDS in Sub-Saharan Afri-
ca were also identified. It was concluded that to achieve 
the 90-90-90 goals set by UNAIDS to help end the AIDS 
epidemic in the world, PrEP offers a new and novel way 
for HIV prevention, and its implementation across all Af-
rican countries is urgently needed for the prevention of 
HIV/AIDS in Sub-Saharan Africa.
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For instance, in 2017, 940 000 people died from HIV-
related causes worldwide; also, there were around 
36.9 million people living with HIV towards the end of 
2017, with 1.8 million people newly infected in 2017 
worldwide. Unfortunately, Africa is the most affected 
continent with the HIV infection epidemic. With 25.7 
million people living with HIV in 2017, the African con-
tinent likewise represents more than 66% of the world-
wide aggregate of new HIV infections cases (2). The 
aforementioned statistics about HIV/AIDS is disturbing. 
Although, on the positive side, between the year 2000 
and 2017, new HIV infections were reduced by 36%, and 
HIV-related deaths diminished by 38%, with 11.4 million 
lives spared because of the antiretroviral therapy (ART). 
However, the most disturbing is that sub Saharan Afri-
can countries still recorded and continues to record the 
highest number of HIV infection and deaths from HIV/
AIDS. With the hope to help in reducing the number of 
HIV infections in Sub-Saharan Africa countries, this re-
view looked at the urgent need for the use of pre-expo-
sure prophylaxis (PrEP) for the prevention of HIV/AIDS in 
Sub-Saharan African countries.
2.  Sources of Information
Literature was retrieved in Web of Science, Google and 
Spring Link databases. Furthermore, major interna-
tional and national health sites, for example, the World 
Health Organization, Centers for disease control and 
prevention were searched to obtain related informa-
tion. Year of production of Journals was not a factor as 
the researcher needed to get all available data on PrEP. 
Careful screening was done to ensure that significant 
data was incorporated into this review. Subsequently, 
the articles included in this review were limited just to 
those written in English.
Key points
1. PrEP is for people without HIV, but who are at a 
very high risk of getting it from sex, injections and 
drug use, for example, sex workers, people who 
inject drugs (PWID), men who have sex with men 
(MSM), prisoners, women and girls, transgender 
people, children, young people and adolescents, 
and people with disabilities.
2. Sub-Saharan Africa remains the most affected by 
HIV infection with 1 in 25 adults (4.1%) living with 
the virus, accounting for 70% of the people living 
with HIV worldwide (2).
3. PrEP is highly effective for preventing HIV if it is 
used as prescribed, as daily PrEP reduces the 
risk of getting HIV from sex by more than 90%, 
among people who inject drugs, it reduces the 
risk by more than 70%, and the risk of getting HIV 
from sex will be lower if PrEP is combined with 
condoms and other prevention methods (3).
4. To achieve the 90-90-90 goals set by UNAIDS, the 
number of new HIV infections should decrease 
to approximately 500,000 before 2020, and one 
of the major factors for achieving this goal is the 
use of PrEP all over the world.
1.  Introduction
Human immunodeficiency virus infection and acquired 
immune deficiency syndrome (HIV/AIDS) is a range of 
conditions caused by an infection with the human im-
munodeficiency virus (HIV) (1). Importantly, HIV is an 
infection that came into existence decades back from 
a virus that infected chimpanzees; it spread across the 
African countries in the late 1970s, and is currently en-
demic around the world, with the highest occurrence in 
Africa. HIV causes ailment because it destroys the basic 
immune system cells in the body, and after a long pe-
riod of time, the HIV virus overpowers it. After the initial 
infection, one may not have any side effects or may ex-
perience flu like disease for a short period of time. HIV 
continues to be a major public health problem across 
the world, having claimed over of 35million lives (2).
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preventing HIV if used as prescribed, but it is much less 
effective when not taken consistently or regularly. A 
combination of two HIV medicines (tenofovir and em-
tricitabine), sold under the name Truvada®, is approved 
for daily use as PrEP to help prevent an HIV-negative 
person from getting HIV from a sexual or injection-drug-
using partner who is positive (3, 4).
Multiple studies have affirmed that PrEP is highly ef-
fective for preventing HIV if it is used as prescribed, but 
PrEP is much less effective when it is not taken consist-
ently as required. Significantly, daily PrEP reduces the 
risk of getting infected with HIV from sex by more than 
90%, among people who inject drugs, it reduces the risk 
of HIV infection by more than 70%, and the risk of get-
ting HIV from sex will be lower if PrEP is combined with 
condoms and other HIV prevention methods (3).
3.  Review on the need for the use of 
pre-exposure prophylaxis (PrEP) 
in the prevention of HIV/AIDS in 
Sub-Saharan Africa
3.1.  What is pre-exposure prophylaxis 
(PrEP)
Pre-exposure prophylaxis (PrEP) is a term used when 
people at a very high risk of HIV take HIV medicines 
daily to reduce their chances of getting infected with 
the deadly virus. Importantly, PrEP can stop HIV from 
taking hold and spreading throughout the body of an 
individual (3). Furthermore, PrEP is highly effective for 
Figure 1. Sub-Saharan Africa remains most affected by HIV infection with 1 in 25 adults (4.1%) 
living with the virus, accounting for 70% of the people living with HIV worldwide. (2)
Picture Source: World Health Organization (2017).
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days of daily use, for receptive vaginal sex and injection 
drug use; PrEP reaches maximum protection at about 
twenty days of daily use (3, 4). Although, no data are yet 
available about how long PrEP takes to reach maximum 
protection for insertive anal or insertive vaginal sex (3).
3.3.  The need for the use of PrEP in the 
prevention of HIV/AIDS in Sub-Saharan 
Africa 
Africa is the most affected continent with HIV infection, 
with 25.7 million individuals living with HIV in 2017 (2). 
The African continent likewise represents more than 66% 
of the worldwide aggregate of new HIV infections (2). Dif-
ferent preventive measures for the prevention of HIV/AIDS, 
for example, the use of condoms, has been employed over 
the years, yet, the number of infection cases is still rising in 
African countries. Fortunately, through continuous and as-
siduous efforts of researchers in the field of HIV/AIDS pre-
vention, they have provided the world with a new preven-
tive measure, which is pre-exposure prophylaxis (PrEP). 
Clinical trials have found that PrEP is highly effective in re-
ducing the risk of HIV infection across types of exposures 
(6). Also, randomized clinical trials have demonstrated the 
efficacy of antiretroviral pre-exposure prophylaxis (PrEP) 
in preventing HIV infection among men who have sex with 
3.2.  Who needs pre-exposure prophylaxis 
(PrEP)
For those at a very high risk of HIV infection, for exam-
ple: sex workers, people who injects drugs (PWID), men 
who have sex with men (MSM), prisoners, women and 
girls, transgender people, children, young people and 
adolescents, and people with disabilities, PrEP can sig-
nificantly reduce their risk of HIV infection if taken daily 
and consistently as required (3, 5). 
Notably, vaccines and PrEP are different; a vaccine 
modifies and gets the body to fight off infection for sev-
eral years. For PrEP, one takes a pill every day by mouth. 
The pill that has been proven to be safe, and with effi-
cacy to help block HIV infection is called Truvada (3, 4). 
Truvada is a combination of two drugs (tenofovir and 
emtricitabine). Importantly, if PrEP is taken daily, the 
presence of the medicine in the bloodstream often stop 
HIV from taking hold and spreading in the body system 
of the user (3, 4). Unfortunately, if PrEP is not used every 
day as required, there may not be enough medicine in 
the bloodstream to block the HIV virus, but when taken 
every day and consistently, PrEP is found to be safe 
and highly effective in preventing HIV infection among 
users (3, 4). Significantly, PrEP reaches maximum pro-
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Figure 2. Regulatory Status of TDF/FTC for pre-exposure prophylaxis (PrEP)
Picture Source: AVAC: Global Advocacy for HIV Prevention (2018).
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tion, recent research data suggests that PrEP, combined 
with other prevention strategies, holds promise in helping 
to curtail the HIV epidemic, as a randomized, controlled 
trial of a topical pericoital antiretroviral microbicide gel 
decreased HIV incidence among at-risk heterosexual 
South African women (11). The rate of HIV infection can 
be reduced across the world, and to achieve the 90-90-90 
goals set by UNAIDS, the number of new HIV infections 
needs to decrease at least to approximately 500,000 by 
2020. One of the major prerequisites to achieve this goal 
is pre-exposure prophylaxis (PrEP) (12). 
3.4.  Update on the implementation of PrEP 
for the prevention of HIV/AIDs in  
Sub-Saharan Africa 
Pilot PrEP projects have been underway in some African 
countries for several years, but it has only been since 
late 2017 that some African countries, notably Kenya 
and South Africa, and also Swaziland, have started se-
rious PrEP availability programmes for wider popula-
tions who are at risk of HIV infection. For example, in 
South Africa, approximately 25,000 to 30,000 people 
have started taking PrEP, Kenya has initiated PrEP in 
about 25,000 people, Zimbabwe in about 5,000, and 
2,250 people in Swaziland have been assessed for PrEP, 
and if all of them start it, this will be about three times 
the number per head of the population compared with 
Kenya (13). Furthermore, Lesotho, Zambia, and Sen-
egal have also started PrEP programmes, either among 
targeted populations such as sex workers, or among 
the general population at-risk (13). Unfortunately, the 
number of African countries that have started PrEP pro-
grammes is far lesser compared to fifty-four countries 
in the continent. To achieve the 90-90-90 goals set by 
UNAIDS to help end the AIDS epidemic, more African 
countries should be encouraged and assisted with the 
personnel, materials and funds by the World Health Or-
ganization (WHO), and other major health international 
agencies to set up, and start PrEP programmes in the 
coming years, since the African continent has the high-
est number of HIV infections and deaths from HIV/AIDS.
3.5. Barriers to the implementation of PrEP 
for the prevention of HIV/AIDs in  
Sub-Saharan Africa 
Socio-economic factors and poor governmental policy 
remain major barriers to widespread implementation 
of pre-exposure prophylaxis in Africa. Although, other 
probable factors hindering the implementation of PrEP 
men (MSM) (7). According to a cross sectional study, pre-
exposure prophylaxis (PrEP) can reduce HIV transmission 
risk for many gay, bisexual and other men who have sex 
with men (8). Furthermore, results from a comparative 
pre-exposure prophylaxis efficacy study against HIV-1 
vaginal transmission revealed that daily oral antiretroviral 
(ARV) drugs for pre-exposure prophylaxis (PrEP) has prov-
en efficacy for diverse groups of high-risk individuals (9). 
Notably, oral pre-exposure prophylaxis (PrEP) is an effec-
tive strategy that should be employed to reduce the risk of 
HIV transmission in high risk individuals. However, the ef-
fectiveness of oral pre-exposure prophylaxis is highly de-
pendent on the users’ adherence. Also, oral pre-exposure 
prophylaxis should be delivered within a holistic interven-
tion (10). For a higher chance of prevention of HIV infec-
Figure 3. Pre-exposure prophylaxis (PrEP) at a glance
Picture Source: Centers for disease control and prevention (CDC) (2018). 
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to the PrEP programmes as users of PrEP needs to 
take the drug daily, and frequent medical check-
ups are required to check the progress of the drug, 
and to look for signs and symptoms of side effects. 
6. Funding
 ▶ Many of the African countries are running a bud-
get deficit, and as such, the budget allocated for 
health is so small that it is not even enough for 
the overall health sector. The setting up of the 
PrEP programme requires substantial amount of 
money to buy the drugs and other materials used 
for PrEP. In a situation where funds are not ava-
ilable, most of the African countries find it diffi-
cult to start the PrEP programme, unless there 
is assistance from international health agencies.
4. Conclusions
Studies have affirmed that PrEP is highly effective for 
preventing HIV, as daily PrEP reduces the risk of get-
ting HIV infection from sex by more than 90%, among 
people who inject drugs it reduces the risk by more 
than 70%, the risk of getting HIV from sex can be lower 
if PrEP is combined with condoms and other preven-
tion methods (3). Sub-Saharan Africa continues to be 
the continent with the highest cases of infections and 
deaths from HIV/AIDS even after the implementation 
of previous HIV/AIDS prevention methods. To achieve 
the 90-90-90 goals set by UNAIDS to help end the AIDS 
epidemic in the world, this review concluded that PrEP 
offers a new way of prevention, and its implementation 
across all African countries is urgently needed for the 
prevention of HIV/AIDs in Sub-Saharan Africa.
5.  Recommendations 
Consequent upon the review of literature, the following 
recommendations are proffered:
1. There should be the political need and will on the 
part of the government to create a legal basis, and 
the requirements to invest massively in the health 
sector and the PrEP programme. This could be 
achieved by making sure that the health budget is 
increased, and expended in the right way.
for the prevention of HIV/AIDs in Sub-Saharan Africa are 
discussed as follows:
1. Experience of side effects
 ▶ In some African countries that have started the 
PrEP programmes, experience of side effects was 
a major factor for the discontinuance of the tre-
atment in Kenya and South Africa. For example, in 
South Africa, among those who had stopped PrEP, 
side effects were by far the most common reason 
to stop among FSWs and MSM, as three-quarters of 
FSWs and 87% of MSM said that side effects inclu-
ding gastrointestinal upset, nausea, dizziness, 
running stomach, darkening of the skin, and hea-
daches were their main reason for stopping PrEP. 
For instance, one PrEP taker stated that “I took the 
bottle halfway due to the side effects.”(13).
2. Fears
 ▶ Another factor impeding the use of PrEP for the pre-
vention of HIV/AIDs in Sub-Saharan Africa among 
users that have started the programme in African 
countries is imaginary beliefs and phobia among 
the populace. For instance, people feared that PrEP 
intake might cause impotence, sterility or being 
used as a specimen of HIV control measures.
3. Stigmatization
 ▶ Stigmatization has been a long-lasting factor 
impeding the eradication of HIV/AIDS epidemic 
in Africa, and now, it is also a concern for the 
administration of PrEP. This is due to social di-
sapproval among the populace. For example, 
one woman recounted that “When I informed my 
husband, he refused and told me that he should 
not find me using it. So, I started taking the drug 
in secret. When he came to know about it, when 
he saw that bottle he beat me to an extent of bre-
aking my nose” (13).
4. Proximity to PrEP centers
 ▶ Another major challenge for the usage of PrEP 
for the prevention of HIV/AIDs in Sub-Saharan 
Africa is the proximity to places where the PrEP 
centers are located. Since there are few PrEP 
centers around, people have difficulty in tran-
sporting themselves to locations where these 
centers are located.
5. Structural barriers
 ▶ There are deficiency and depleted health buildin-
gs in many African countries, bad road network 
hinders people from readily accessing hospital fa-
cilities, and PrEP centers. This may be a hindrance 
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2. PrEP users should be told about side effects in 
pre-PrEP counseling sessions, and how to mana-
ge those side effects should be clearly explained 
to the users.
3. Massive sensitization should be organized to 
enlighten the public about the importance of 
PrEP, and to allay fears the populace might have 
towards the programme in countries where the 
PrEP programmes have begun.
4. African countries should be encouraged and 
assisted with the personnel, materials and funds 
to buy PrEP drugs by the WHO, and other major 
health international agencies to set up, and start 
PrEP programmes
5. As a matter of urgency, PrEP programmes should 
be started in all African countries with the highest 
number of HIV/AIDS infections and deaths, e.g., 
Lesotho, Botswana, Namibia, Zimbabwe, Zambia, 
Mozambique, Malawi, Uganda, Nigeria, and so on, 
to achieve the 90-90-90 goals set by UNAIDS to 
help end the AIDS epidemic in the world.
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PrEP-a za prevenciju HIV/AIDS-a u subsaharskoj Africi. 
Zaključeno je da je za postizanje ciljeva 90-90-90 koje je 
UNAIDS postavio kako bi se okončala epidemija AIDS-a 
u svijetu, PrEP nudi novi način prevencije HIV-a, a njezi-
na primjena u svim afričkim zemljama hitno je potreb-
na za prevenciju HIV/AIDS-a u subsaharskoj Africi.
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Sažetak
Virus humane imunodeficijencije (HIV) je infekcija koja 
je nastala prije nekoliko desetljeća; proširila se afričkim 
zemljama kasnih sedamdesetih godina i trenutno je 
endemska bolest širom svijeta. HIV predstavlja veliki 
javnozdravstveni problem u cijelom svijetu jer je odnio 
više od 35 milijuna života. Krajem 2017. Godine bilo je 
oko 36,9 milijuna osoba koje žive s HIV-om, a subsa-
harska Afrika je i dalje najviše pogođena HIV infekcijom 
s 1 na 25 odraslih osoba(4,1%) koji žive s virusom, što 
čini 70% ljudi koji žive s HIV-om širom svijeta. Nažalost, 
subsaharska Afrika je i dalje kontinent s najvišim 
brojem infekcija i smrti od HIV/AIDS-a, čak i nakon 
provedbe različitih metoda prevencije. Srećom, pre-
ekspozicijska profilaksa (PrEP) svijetu nudi novi način 
ograničavanja epidemije HIV/AIDS-a, budući da je PrEP 
visoko učinkovit u sprječavanju HIV-a ako se koristikako 
je propisano. U ovom se radu raspravlja o hitnoj potre-
bi korištenja PrEP-a u prevenciji HIV/AIDS-a u subsa-
harskoj Africi. To je pregledni rad u kojem se raspravlja 
o značenju PrEP-a, identificirani su ljudi kojima je potre-
ban PrEP, istaknuta je svrha primjene PrEP-a za pre-
venciju HIV/AIDS-a u subsaharskoj Africi te su također 
identificirane moguće prepreke za uspješnu provedbu 
HITNA POTREBA ZA KORIŠTENJEM PREEKSPOZICIJSKE PROFILAKSE (PrEP)  
U PREVENCIJI HIV/AIDS-a U SUBSAHARSKOJ AFRICI
